AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Kanamycin A sulfate is primarily used to treat bacterial infections caused by susceptible organisms. It works by inhibiting bacterial protein synthesis, thereby preventing bacterial growth and replication.
Respiratory Tract Infections: Kanamycin A sulfate may be used to treat respiratory tract infections, including pneumonia, bronchitis, and bronchiectasis caused by susceptible bacteria. It is particularly effective against gram-negative bacteria.
Urinary Tract Infections: This antibiotic can be prescribed for the treatment of urinary tract infections caused by susceptible organisms, such as Escherichia coli, Proteus species, and Klebsiella pneumoniae.
Intra-abdominal Infections: Kanamycin A sulfate may be used as part of the treatment regimen for intra-abdominal infections, including peritonitis and intra-abdominal abscesses, especially in cases where other antibiotics are ineffective or contraindicated.
Skin and Soft Tissue Infections: Kanamycin A sulfate may be used to treat skin and soft tissue infections caused by susceptible bacteria, such as cellulitis, abscesses, and infected wounds.
Eye Infections: Ophthalmic preparations of kanamycin A sulfate are available for the treatment of eye infections, including bacterial conjunctivitis and keratitis caused by susceptible organisms.
Tuberculosis: Kanamycin A sulfate is sometimes used as part of combination therapy for the treatment of drug-resistant tuberculosis, particularly in cases where other first-line and second-line tuberculosis drugs are ineffective.
Cystic Fibrosis: In patients with cystic fibrosis, kanamycin A sulfate may be used to treat chronic respiratory infections caused by Pseudomonas aeruginosa and other bacteria commonly associated with the condition.
Hospital-acquired Infections: Kanamycin A sulfate may be used in hospitals to treat infections caused by multidrug-resistant bacteria, including those acquired in healthcare settings.
Adverse Effects: Common side effects associated with kanamycin A sulfate include nephrotoxicity (kidney damage), ototoxicity (hearing loss or vestibular dysfunction), and neurotoxicity (central nervous system effects). Monitoring of kidney function and hearing is necessary during treatment.
Resistance: The emergence of bacterial resistance to kanamycin A sulfate is a concern with prolonged or inappropriate use. Resistance monitoring and prudent antibiotic use are essential to mitigate the development of resistant bacterial strains.
Pregnancy and Lactation: Kanamycin A sulfate is generally considered safe for use during pregnancy and lactation when the benefits outweigh the risks. However, healthcare providers should weigh the potential risks and benefits before prescribing kanamycin A sulfate to pregnant or breastfeeding women.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 0.9 | 0.9 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.3 | 1 |
| Allergies | 0.3 | 0.6 | -1 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 1.1 | 1.7 | -0.55 |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 0.3 | 0.9 | -2 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 1.1 | 0.6 | 0.83 |
| Atherosclerosis | 0.6 | 0.6 | |
| Atrial fibrillation | 0.9 | 1.2 | -0.33 |
| Autism | 1 | 1.8 | -0.8 |
| Autoimmune Disease | 0.3 | 0.3 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.6 | 0.6 | |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0 | 0 |
| Carcinoma | 1.4 | 0.3 | 3.67 |
| Celiac Disease | 0.6 | 0.6 | 0 |
| Cerebral Palsy | 0.6 | 0.3 | 1 |
| Chronic Fatigue Syndrome | 0.9 | 1.3 | -0.44 |
| Chronic Kidney Disease | 0.4 | 1 | -1.5 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.6 | 0.5 |
| Chronic Urticaria (Hives) | 0.3 | 0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.3 | 0 |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 1.6 | 0.6 | 1.67 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.6 | 0.9 | -0.5 |
| COVID-19 | 1.2 | 2.1 | -0.75 |
| Crohn's Disease | 1.4 | 1.2 | 0.17 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.2 | 0.6 | -2 |
| Denture Wearers Oral Shifts | 0.8 | 0.8 | |
| Depression | 1.3 | 1.5 | -0.15 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 0.6 | 0 |
| Endometriosis | 0.6 | 0.6 | |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 0.9 | 0.3 | 2 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.4 | 0.3 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 0.4 | 0.5 |
| gallstone disease (gsd) | 0.3 | -0.3 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 0.9 | 0.6 | 0.5 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 0.3 | 0.6 | -1 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 1.1 | 0.3 | 2.67 |
| Hashimoto's thyroiditis | 0.7 | 0.7 | 0 |
| Heart Failure | 0.8 | 0.6 | 0.33 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| hyperglycemia | 0.3 | 0.3 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.7 | 0.9 | -0.29 |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | |
| Inflammatory Bowel Disease | 1.7 | 1.9 | -0.12 |
| Insomnia | 0.9 | 0.9 | 0 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 0.9 | 0.6 | 0.5 |
| ischemic stroke | 0.6 | 0.6 | 0 |
| Liver Cirrhosis | 1.7 | 1.2 | 0.42 |
| Long COVID | 1.5 | 1.2 | 0.25 |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.5 | 0.5 | |
| ME/CFS with IBS | 0.3 | 0.3 | 0 |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 1.3 | 1.2 | 0.08 |
| Mood Disorders | 1.2 | 1.5 | -0.25 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.1 | 1.2 | -0.09 |
| myasthenia gravis | 0.3 | 0.3 | |
| neuropathic pain | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.2 | 0.9 | 0.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.3 | 1.4 | -0.08 |
| obsessive-compulsive disorder | 0.6 | 1 | -0.67 |
| Osteoarthritis | 1 | 0.6 | 0.67 |
| Osteoporosis | 0.3 | 0.6 | -1 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 1.3 | 2.2 | -0.69 |
| Polycystic ovary syndrome | 0.9 | 0.9 | 0 |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.9 | 0.9 | |
| Psoriasis | 0.3 | 0.9 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 1.2 | -0.09 |
| Rosacea | 0.1 | 0.1 | |
| Schizophrenia | 1.2 | 0.3 | 3 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.3 | 0.6 | -1 |
| Sleep Apnea | 0.3 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.3 | 1 |
| Systemic Lupus Erythematosus | 1.2 | 0.1 | 11 |
| Tic Disorder | 0.3 | 0.3 | |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 0.9 | 0.6 | 0.5 |
| Type 2 Diabetes | 1.4 | 0.9 | 0.56 |
| Ulcerative colitis | 1.2 | 0.6 | 1 |
| Unhealthy Ageing | 1.5 | 0.6 | 1.5 |
| Vitiligo | 0.6 | 0.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
